Merck-NewLink Ebola vaccine Phase III trial to start March 7

March 5, 2015 10:04 AM

1 0

GENEVA/LONDON (Reuters) - Final stage of testing of an experimental Ebola vaccine being developed by Merck and NewLink Genetics will begin in Guinea on March 7, the World Health Organization said on Thursday.

Signaling global health authorities' determination to push ahead with vaccine trials despite a sharp drop in cases in the West Africa epidemic, the WHO said a second shot, developed by GlaxoSmithKline will be tested "in a sequential study, as supply becomes available".

Read more

To category page